AAPL344.82-2.29 (-0.66%) ▼|ABBV285.63-0.76 (-0.27%) ▼|ABT103.10-1.78 (-1.70%) ▼|ACN235.16-12.07 (-4.88%) ▼|ADBE248.36-10.26 (-3.97%) ▼|AMAT395.93+8.34 (+2.15%) ▲|AMD560.26+28.98 (+5.45%) ▲|AMGN447.95+3.32 (+0.75%) ▲|AMT183.83-4.45 (-2.36%) ▼|AMZN253.10+4.01 (+1.61%) ▲|AVGO342.33+13.16 (+4.00%) ▲|AXP312.91-2.14 (-0.68%) ▼|BA168.18-20.13 (-10.69%) ▼|BAC50.68+0.16 (+0.32%) ▲|BKNG150.14-3.00 (-1.96%) ▼|BLK1,136.05+8.39 (+0.74%) ▲|BMY61.55-0.06 (-0.10%) ▼|BNY147.58+0.40 (+0.27%) ▲|BRK-B542.99-5.57 (-1.02%) ▼|C122.69+1.65 (+1.36%) ▲|CAT713.31+21.18 (+3.06%) ▲|CL92.17-0.93 (-1.00%) ▼|CMCSA21.84-0.21 (-0.95%) ▼|COF203.44+1.09 (+0.54%) ▲|COP147.96-3.41 (-2.25%) ▼|COST992.13-13.03 (-1.30%) ▼|CRM240.89-6.72 (-2.71%) ▼|CSCO111.38+1.14 (+1.03%) ▲|CVS91.13-1.40 (-1.51%) ▼|CVX228.23-3.78 (-1.63%) ▼|DE639.58-1.67 (-0.26%) ▼|DHR232.00-0.97 (-0.42%) ▼|DIS110.23-0.17 (-0.15%) ▼|DUK124.80+0.36 (+0.29%) ▲|EMR166.27+4.57 (+2.83%) ▲|FDX307.10+6.52 (+2.17%) ▲|GD354.89-2.15 (-0.60%) ▼|GE297.66+9.23 (+3.20%) ▲|GEV895.08+40.46 (+4.73%) ▲|GILD159.08+0.39 (+0.25%) ▲|GM80.54+4.23 (+5.54%) ▲|GOOG316.83+2.64 (+0.84%) ▲|GOOGL320.58+3.78 (+1.19%) ▲|GS911.77+18.49 (+2.07%) ▲|HD318.50-0.88 (-0.28%) ▼|HON218.81-0.47 (-0.21%) ▼|IBM250.25-3.19 (-1.26%) ▼|INTC93.74+3.27 (+3.61%) ▲|INTU328.45-11.44 (-3.37%) ▼|ISRG445.88-5.75 (-1.27%) ▼|JNJ268.73+2.43 (+0.91%) ▲|JPM335.79+1.75 (+0.52%) ▲|KO91.18-1.52 (-1.64%) ▼|LIN508.65+1.09 (+0.21%) ▲|LLY1,281.91+2.77 (+0.22%) ▲|LMT622.99-12.21 (-1.92%) ▼|LOW198.18-0.04 (-0.02%) ▼|LRCX240.85+3.35 (+1.41%) ▲|MA609.85-3.65 (-0.59%) ▼|MCD249.47-1.36 (-0.54%) ▼|MDLZ62.35-0.62 (-0.98%) ▼|MDT93.95-0.84 (-0.89%) ▼|META620.19-10.37 (-1.64%) ▼|MMM171.58-1.21 (-0.70%) ▼|MO73.49-0.13 (-0.18%) ▼|MRK141.82+1.21 (+0.86%) ▲|MS186.91+3.42 (+1.86%) ▲|MSFT531.33-1.27 (-0.24%) ▼|MU928.76+25.06 (+2.77%) ▲|NEE82.42+0.38 (+0.46%) ▲|NFLX62.52-1.38 (-2.16%) ▼|NKE37.56-0.35 (-0.92%) ▼|NOW154.78-3.40 (-2.15%) ▼|NVDA217.94+1.94 (+0.90%) ▲|ORCL130.53+4.47 (+3.55%) ▲|PEP133.50-1.96 (-1.45%) ▼|PFE29.80+0.01 (+0.03%) ▲|PG159.23-0.69 (-0.43%) ▼|PLTR198.73-0.11 (-0.06%) ▼|PM202.62+0.75 (+0.37%) ▲|QCOM184.17+4.57 (+2.54%) ▲|RTX194.60-2.88 (-1.46%) ▼|SBUX103.04+0.35 (+0.34%) ▲|SCHW89.30-0.43 (-0.48%) ▼|SO92.65+0.08 (+0.09%) ▲|SPG212.28-0.41 (-0.19%) ▼|T20.94+0.09 (+0.43%) ▲|TMO693.02+8.13 (+1.19%) ▲|TMUS146.83-0.10 (-0.07%) ▼|TSLA407.46+15.84 (+4.04%) ▲|TXN308.91+10.79 (+3.62%) ▲|UBER65.78-0.35 (-0.53%) ▼|UNH410.39-0.31 (-0.08%) ▼|UNP299.88+2.91 (+0.98%) ▲|UPS106.09+5.77 (+5.75%) ▲|USB59.74+0.04 (+0.07%) ▲|V401.86-2.30 (-0.57%) ▼|VZ43.93+0.83 (+1.93%) ▲|WFC82.66+0.01 (+0.01%) ▲|WMT119.32-0.97 (-0.81%) ▼|XOM179.91-4.63 (-2.51%) ▼|AAPL344.82-2.29 (-0.66%) ▼|ABBV285.63-0.76 (-0.27%) ▼|ABT103.10-1.78 (-1.70%) ▼|ACN235.16-12.07 (-4.88%) ▼|ADBE248.36-10.26 (-3.97%) ▼|AMAT395.93+8.34 (+2.15%) ▲|AMD560.26+28.98 (+5.45%) ▲|AMGN447.95+3.32 (+0.75%) ▲|AMT183.83-4.45 (-2.36%) ▼|AMZN253.10+4.01 (+1.61%) ▲|AVGO342.33+13.16 (+4.00%) ▲|AXP312.91-2.14 (-0.68%) ▼|BA168.18-20.13 (-10.69%) ▼|BAC50.68+0.16 (+0.32%) ▲|BKNG150.14-3.00 (-1.96%) ▼|BLK1,136.05+8.39 (+0.74%) ▲|BMY61.55-0.06 (-0.10%) ▼|BNY147.58+0.40 (+0.27%) ▲|BRK-B542.99-5.57 (-1.02%) ▼|C122.69+1.65 (+1.36%) ▲|CAT713.31+21.18 (+3.06%) ▲|CL92.17-0.93 (-1.00%) ▼|CMCSA21.84-0.21 (-0.95%) ▼|COF203.44+1.09 (+0.54%) ▲|COP147.96-3.41 (-2.25%) ▼|COST992.13-13.03 (-1.30%) ▼|CRM240.89-6.72 (-2.71%) ▼|CSCO111.38+1.14 (+1.03%) ▲|CVS91.13-1.40 (-1.51%) ▼|CVX228.23-3.78 (-1.63%) ▼|DE639.58-1.67 (-0.26%) ▼|DHR232.00-0.97 (-0.42%) ▼|DIS110.23-0.17 (-0.15%) ▼|DUK124.80+0.36 (+0.29%) ▲|EMR166.27+4.57 (+2.83%) ▲|FDX307.10+6.52 (+2.17%) ▲|GD354.89-2.15 (-0.60%) ▼|GE297.66+9.23 (+3.20%) ▲|GEV895.08+40.46 (+4.73%) ▲|GILD159.08+0.39 (+0.25%) ▲|GM80.54+4.23 (+5.54%) ▲|GOOG316.83+2.64 (+0.84%) ▲|GOOGL320.58+3.78 (+1.19%) ▲|GS911.77+18.49 (+2.07%) ▲|HD318.50-0.88 (-0.28%) ▼|HON218.81-0.47 (-0.21%) ▼|IBM250.25-3.19 (-1.26%) ▼|INTC93.74+3.27 (+3.61%) ▲|INTU328.45-11.44 (-3.37%) ▼|ISRG445.88-5.75 (-1.27%) ▼|JNJ268.73+2.43 (+0.91%) ▲|JPM335.79+1.75 (+0.52%) ▲|KO91.18-1.52 (-1.64%) ▼|LIN508.65+1.09 (+0.21%) ▲|LLY1,281.91+2.77 (+0.22%) ▲|LMT622.99-12.21 (-1.92%) ▼|LOW198.18-0.04 (-0.02%) ▼|LRCX240.85+3.35 (+1.41%) ▲|MA609.85-3.65 (-0.59%) ▼|MCD249.47-1.36 (-0.54%) ▼|MDLZ62.35-0.62 (-0.98%) ▼|MDT93.95-0.84 (-0.89%) ▼|META620.19-10.37 (-1.64%) ▼|MMM171.58-1.21 (-0.70%) ▼|MO73.49-0.13 (-0.18%) ▼|MRK141.82+1.21 (+0.86%) ▲|MS186.91+3.42 (+1.86%) ▲|MSFT531.33-1.27 (-0.24%) ▼|MU928.76+25.06 (+2.77%) ▲|NEE82.42+0.38 (+0.46%) ▲|NFLX62.52-1.38 (-2.16%) ▼|NKE37.56-0.35 (-0.92%) ▼|NOW154.78-3.40 (-2.15%) ▼|NVDA217.94+1.94 (+0.90%) ▲|ORCL130.53+4.47 (+3.55%) ▲|PEP133.50-1.96 (-1.45%) ▼|PFE29.80+0.01 (+0.03%) ▲|PG159.23-0.69 (-0.43%) ▼|PLTR198.73-0.11 (-0.06%) ▼|PM202.62+0.75 (+0.37%) ▲|QCOM184.17+4.57 (+2.54%) ▲|RTX194.60-2.88 (-1.46%) ▼|SBUX103.04+0.35 (+0.34%) ▲|SCHW89.30-0.43 (-0.48%) ▼|SO92.65+0.08 (+0.09%) ▲|SPG212.28-0.41 (-0.19%) ▼|T20.94+0.09 (+0.43%) ▲|TMO693.02+8.13 (+1.19%) ▲|TMUS146.83-0.10 (-0.07%) ▼|TSLA407.46+15.84 (+4.04%) ▲|TXN308.91+10.79 (+3.62%) ▲|UBER65.78-0.35 (-0.53%) ▼|UNH410.39-0.31 (-0.08%) ▼|UNP299.88+2.91 (+0.98%) ▲|UPS106.09+5.77 (+5.75%) ▲|USB59.74+0.04 (+0.07%) ▲|V401.86-2.30 (-0.57%) ▼|VZ43.93+0.83 (+1.93%) ▲|WFC82.66+0.01 (+0.01%) ▲|WMT119.32-0.97 (-0.81%) ▼|XOM179.91-4.63 (-2.51%) ▼|
10 C
New York
Wednesday, October 28, 2026

Tag: protein

D-Bal Max 2025: Exploring the Science and Safety behind a Popular And Legal Dianabol Steroid For Muscle Growth

Glasgow, June 15, 2025 (GLOBE NEWSWIRE) --

In the quest for enhanced athletic performance and muscle growth, many fitness enthusiasts and bodybuilders turn to supplements. D-Bal Max has emerged as a noteworthy option that claims to replicate the muscle-building benefits of anabolic steroids, but with a natural and safer approach.

Investigational combination of first-in-class bispecifics TALVEY® and TECVAYLI® shows deep and durable responses in heavily pretreated multiple myeloma patients with extramedullary disease

Results from the Phase 2 RedirecTT-1 study demonstrate deep responses with 78.9 percent overall response rate through dual targeting of GPRC5D and BCMA Data signal...

[Ad hoc announcement pursuant to Art. 53 LR] Roche provides safety update on Elevidys™ gene therapy for Duchenne muscular dystrophy in non-ambulatory patients

Basel, 15 June 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today new dosing restrictions, effective immediately, for ELEVIDYS™ (delandistrogene moxeparvovec), for non-ambulatory Duchenne muscular dystrophy (DMD) patients, irrespective of age, in both clinical and commercial settings. In the commercial setting, non-ambulatory patients should no longer receive Elevidys. In the clinical trial setting, enrolment and dosing of non-ambulatory patients will be immediately paused until additional risk mitigation measures (e.g. immune modulatory treatment) are implemented in the study protocol. Health authorities, investigators and physicians are being informed so that patient care can be quickly adjusted.

Nurix Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN FRANCISCO, June 13, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, the next frontier in innovative drug design aimed at improving treatment options for patients with cancer and inflammatory diseases, today announced that on June 10, 2025, the company granted inducement awards to seventeen new employees. The grants were made pursuant to Nurix’s 2024 Equity Inducement Plan as an inducement material to the employees’ acceptance of employment with Nurix and were approved by the Compensation Committee of Nurix’s Board of Directors in accordance with Nasdaq Listing Rule 5635(c)(4).

CureLab Veterinary’s ElenaVet™ Gene Therapy Delivers 90% Success in Pet-Dog Osteoarthritis Study

Frontiers in Veterinary Science paper reports rapid, significant pain relief with weekly p62-plasmid injections and no significant side-effects BOSTON, June 13, 2025 /PRNewswire/ -- CureLab...

BioArctic to initiate next cohorts in exidavnemab Phase 2a study after positive safety review

STOCKHOLM, June 13, 2025 /PRNewswire/ -- BioArctic AB (publ) (NASDAQ Stockholm: BIOA B) announced today that the interim safety review of the clinical Phase...

European Commission Grants Orphan Drug Designation to Florbetaben (18F) for Diagnosis of ATTR Amyloidosis

Florbetaben (18F) has been granted Orphan drug designation for the diagnosis of ATTR amyloidosisFlorbetaben (18F) previously received orphan drug designation as a diagnostic agent...

Bay Area Lyme Foundation Announces National Winner of the 2025 Emerging Leader Award to Develop a Much-Needed Rapid, Low-Cost, Easy-to-Use Lyme Disease Test

Winner Chao Wang of Arizona State University will receive $150,000 to evaluate a unique diagnostic that uses gold nanoparticles and has been proven in other infectious diseases
Winner Chao Wang of Arizona State University will receive $150,000 to evaluate a unique diagnostic that uses gold nanoparticles and has been proven in other infectious diseases

MolecuLight® Imaging Significantly Improves Outcomes and Cuts Costs for Deep Sternal Wound Infections in Taiwan Study; Signals Expansion into Surgical Applications

PITTSBURGH and TAIPEI, June 12, 2025 /PRNewswire/ - MolecuLight Corp., a global pioneer in point-of-care fluorescence imaging for wound care, and its Taiwanese distributor,...

Amid crisis and cost cutting fatigue, Europeans splash out on comfort and indulgence

New Circana 'Eat Play Love' report highlights increased demand for foods, toys and beauty products that provide mini moments of bliss and escape from...

Fapon Biopharma to Showcase Differentiated Pipeline, Including Phase 1 Immunocytokine FP008, and Innovative Technology Platforms at BIO 2025

BOSTON, June 12, 2025 /PRNewswire/ -- Fapon Biopharma, a clinical-stage biotech company innovating therapeutic antibodies and fusion proteins, is pleased to announce its participation...

Levicept to Present Further Analysis from Phase II Trial of Novel Neurotrophin-3 Inhibitor, LEVI-04, at EULAR

SANDWICH, United Kingdom, June 12, 2025 (GLOBE NEWSWIRE) -- Levicept Ltd, a biotechnology company focused on the development of LEVI-04, a first-in-class treatment for osteoarthritis, is to present new data from its large-scale Phase II trial of LEVI-04 at EULAR, the European Congress of Rheumatology in Barcelona, Spain.

Significant efficacy benefit of IMBRUVICA® (ibrutinib) plus venetoclax versus acalabrutinib plus venetoclax in frontline treatment of patients with chronic lymphocytic leukaemia suggested by indirect...

Cross-study findings indicate significant clinical benefit of frontline fixed-duration ibrutinib plus venetoclax with improved likelihood of undetectable minimal residual disease and progression-free survival versus acalabrutinib plus venetoclax1

Insmed Announces Pricing of $750 Million Public Offering of Common Stock

BRIDGEWATER, N.J., June 11, 2025 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to...

- A word from our sponsors -

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsProtein